

## DAFTAR PUSTAKA

- Afshar, A.R., Pekmezci, M., Bloomer, M.M., Cadenas, N.J., Stevers, M., Banerjee, A., Roy, R., Olshen, A.B., Van Ziffle, J., Onodera, C., Devine, W.P., Grenert, J.P., Bastian, B.C., Solomon, D.A., Damato, B.E., 2020. Next-Generation Sequencing of Retinoblastoma Identifies Pathogenic Alterations beyond RB1 Inactivation That Correlate with Aggressive Histopathologic Features. *Ophthalmology* 127, 804–813. <https://doi.org/10.1016/j.ophtha.2019.12.005>
- Agustina, R., Dartanto, T., Sitompul, R., Susiloretni, K.A., Suparmi, null, Achadi, E.L., Taher, A., Wirawan, F., Sungkar, S., Sudarmono, P., Shankar, A.H., Thabrany, H., Indonesian Health Systems Group, 2019. Universal health coverage in Indonesia: concept, progress, and challenges. *Lancet Lond. Engl.* 393, 75–102. [https://doi.org/10.1016/S0140-6736\(18\)31647-7](https://doi.org/10.1016/S0140-6736(18)31647-7)
- Ancona-Lezama, D., Dalvin, L., Shields, C., 2020. Modern treatment of retinoblastoma: A 2020 review. *Indian J. Ophthalmol.* 68, 2356. [https://doi.org/10.4103/ijo.IJO\\_721\\_20](https://doi.org/10.4103/ijo.IJO_721_20)
- Aygun, N., Altungoz, O., 2019. MYCN is amplified during S phase, and c-myc is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines. *Mol. Med. Rep.* 19, 345–361. <https://doi.org/10.3892/mmr.2018.9686>
- Biswas, J., Kandalam, M., Mitra, M., Subramanian, K., 2010. Molecular pathology of retinoblastoma. *Middle East Afr. J. Ophthalmol.* 17, 217. <https://doi.org/10.4103/0974-9233.65498>
- Blixt, M.K.E., Hellsand, M., Konjusha, D., Zhang, H., Stenfelt, S., Åkesson, M., Rafati, N., Tararuk, T., Stålhammar, G., All-Eriksson, C., Ring, H., Hallböök, F., 2022. MYCN induces cell-specific tumorigenic growth in RB1-proficient human retinal organoid and chicken retina models of retinoblastoma. *Oncogenesis* 11, 34. <https://doi.org/10.1038/s41389-022-00409-3>
- Brenda Gallie, A.A., Stephanie Kletke, Wai-Ching Lam, 2017. Retinoblastoma for Pediatric Ophthalmologists. *Asia-Pac. J. Ophthalmol.* <https://doi.org/10.22608/APO.201870>
- Chen, D., Pacal, M., Wenzel, P., Knoepfler, P.S., Leone, G., Bremner, R., 2009. Division and apoptosis of E2f-deficient retinal progenitors. *Nature* 462, 925–929. <https://doi.org/10.1038/nature08544>
- de Bloeme, C.M., Jansen, R.W., Cardoen, L., Göricke, S., van Elst, S., Jessen, J.L., Ramasubramanian, A., Skalet, A.H., Miller, A.K., Maeder, P., Uner, O.E., Hubbard, G.B., Grossniklaus, H., Boldt, H.C., Nichols, K.E., Brennan, R.C., Sen, S., Koob, M., Sirin, S., Brisse, H.J., Galluzzi, P., Dommering, C.J., Cysouw, M., Boellaard, R., Dorsman, J.C., Moll, A.C., de Jong, M.C., de Graaf, P., European Retinoblastoma Imaging Collaboration, 2024. Differentiating MYCN-amplified RB1 wild-type retinoblastoma from biallelic RB1 mutant retinoblastoma using MR-based radiomics: a retrospective multicenter case-control study. *Sci. Rep.* 14, 25103. <https://doi.org/10.1038/s41598-024-76933-6>
- De Rosa, P., Severi, F., Zadran, S.K., Russo, M., Aloisi, S., Rigamonti, A., Capranico, G., Milazzo, G., Perini, G., 2023. MYCN Amplification, along with Wild-Type RB1

- Expression, Enhances CDK4/6 Inhibitors' Efficacy in Neuroblastoma Cells. *Int. J. Mol. Sci.* 24, 5408. <https://doi.org/10.3390/ijms24065408>
- Dharmawidiarini, D., Soebago, H.D., 2010. Ocular Survival Rate Penderita Retinoblastoma yang Telah Dilakukan E nukleasi atau Eksenterasi di RSUD Dr. Soetomo Surabaya 7.
- Ewens, K.G., Bhatti, T.R., Moran, K.A., Richards-Yutz, J., Shields, C.L., Eagle, R.C., Ganguly, A., 2017. Phosphorylation of pRb: mechanism for RB pathway inactivation in *MYCN* -amplified retinoblastoma. *Cancer Med.* 6, 619–630. <https://doi.org/10.1002/cam4.1010>
- Fabian, I.D., Onadim, Z., Karaa, E., Duncan, C., Chowdhury, T., Scheimberg, I., Ohnuma, S.-I., Reddy, M.A., Sagoo, M.S., 2018. The management of retinoblastoma. *Oncogene* 37, 1551–1560. <https://doi.org/10.1038/s41388-017-0050-x>
- Global Retinoblastoma Study Group, Fabian, I.D., Abdallah, E., Abdullahi, S.U., Abdulqader, R.A., Adamou Boubacar, S., Ademola-Popoola, D.S., Adio, A., Afshar, A.R., Aggarwal, P., Aghaji, A.E., Ahmad, A., Akib, M.N.R., Al Harby, L., 2020. Global Retinoblastoma Presentation and Analysis by National Income Level. *JAMA Oncol.* 6, 685. <https://doi.org/10.1001/jamaoncol.2019.6716>
- Graff, Z., Giron, V., Miller, K., Pixtun, D., Alejos, A., Luna-Fineman, S., 2023. Toxicity and feasibility of vincristine, etoposide, and carboplatin alternating with vincristine, doxorubicin, and cyclophosphamide in children with advanced retinoblastoma in Guatemala. *Pediatr. Blood Cancer* 70, e30392. <https://doi.org/10.1002/psc.30392>
- Gupta, A.K., Meena, J.P., 2020. A narrative review of retinoblastoma and recent advances in its management. *Pediatr. Med.* 3. <https://doi.org/10.21037/pm-20-79>
- Joseph, B., Kumaramanickavel, G., 2007. 'Insight' into Molecular Genetic Testing in Retinoblastoma. *Int. J. Hum. Genet.* 7, 23–28. <https://doi.org/10.1080/09723757.2007.11885982>
- Joseph, S., Pike, S., Peng, C.-C., Brown, B., Xu, L., Berry, J.L., Chévez-Barrios, P., Hubbard, G.B., Grossniklaus, H.E., 2024. Retinoblastoma with *MYCN* Amplification Diagnosed from Cell-Free DNA in the Aqueous Humor. *Ocul. Oncol. Pathol.* 10, 15–24. <https://doi.org/10.1159/000533311>
- Kaewkhaw, R., Rojanaporn, D., 2020. Retinoblastoma: Etiology, Modeling, and Treatment. *Cancers* 12, 2304. <https://doi.org/10.3390/cancers12082304>
- Kandalam, M., Mitra, M., Subramanian, K., Biswas, J., 2010. Molecular Pathology of Retinoblastoma. *Middle East Afr. J. Ophthalmol.* 17, 217–223. <https://doi.org/10.4103/0974-9233.65498>
- Liu, R., Shi, P., Wang, Z., Yuan, C., Cui, H., 2021. Molecular Mechanisms of *MYCN* Dysregulation in Cancers. *Front. Oncol.* 10, 625332. <https://doi.org/10.3389/fonc.2020.625332>
- Liu, Z., Chen, S.S., Clarke, S., Veschi, V., Thiele, C.J., 2021. Targeting *MYCN* in Pediatric and Adult Cancers. *Front. Oncol.* 10. <https://doi.org/10.3389/fonc.2020.623679>
- Othman, I.S., 2012. Retinoblastoma major review with updates on Middle East management protocols. *Saudi J. Ophthalmol.* 26, 163–175. <https://doi.org/10.1016/j.sjopt.2012.03.002>

- Price, E.A., Patel, R., Scheimberg, I., Kotiloglu Karaa, E., Sagoo, M.S., Reddy, M.A., Onadim, Z., 2021. MYCN amplification levels in primary retinoblastoma tumors analyzed by Multiple Ligation-dependent Probe Amplification. *Ophthalmic Genet.* 42, 604–611. <https://doi.org/10.1080/13816810.2021.1923038>
- Roohollahi, K., De Jong, Y., Van Mil, S.E., Fabius, A.W.M., Moll, A.C., Dorsman, J.C., 2022. High-Level MYCN-Amplified RB1-Proficient Retinoblastoma Tumors Retain Distinct Molecular Signatures. *Ophthalmol. Sci.* 2, 100188. <https://doi.org/10.1016/j.xops.2022.100188>
- Ruiz-Pérez, M.V., Henley, A.B., Arsenian-Henriksson, M., 2017. The MYCN Protein in Health and Disease. *Genes* 8, 113. <https://doi.org/10.3390/genes8040113>
- Rushlow, D.E., Mol, B.M., Kennett, J.Y., Yee, S., Pajovic, S., Thériault, B.L., Prigoda-Lee, N.L., Spencer, C., Dimaras, H., Corson, T.W., Pang, R., Massey, C., Godbout, R., Jiang, Z., Zacksenhaus, E., Paton, K., Moll, A.C., Houdayer, C., Raizis, A., Halliday, W., Lam, W.L., Boutros, P.C., Lohmann, D., Dorsman, J.C., Gallie, B.L., 2013. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. *Lancet Oncol.* 14, 327–334. [https://doi.org/10.1016/S1470-2045\(13\)70045-7](https://doi.org/10.1016/S1470-2045(13)70045-7)
- Schwermer, M., Hiber, M., Dreesmann, S., Rieb, A., Theißen, J., Herold, T., Schramm, A., Temming, P., Steenpass, L., 2019. Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines. *Exp. Cell Res.* 375, 92–99. <https://doi.org/10.1016/j.yexcr.2018.12.018>
- Syed, A., Berry, J., Heegard, S., 2023, 'Retinoblastoma', in *Ophthalmic Pathology and Intraocular Tumors*, American Academy of Ophthalmology, San Francisco., n.d.
- Vempuluru, V.S., Maniar, A., Bakal, K., Kaliki, S., 2024. Role of MYCN in retinoblastoma: A review of current literature. *Surv. Ophthalmol.* 69, 697–706. <https://doi.org/10.1016/j.survophthal.2024.05.009>
- Yang, Y., Zhao, J., Zhang, Y., Yv, B., Wang, J., Feng, H., Gao, Y., Yin, M., Tang, J., Li, Y., 2020. MYCN Fish combined with immunohistochemistry is a more prognostic factor for neuroblastoma. <https://doi.org/10.21203/rs.3.rs-62365/v1>
- Yaqoob, N., Mansoor, S., Zia, N., Aftab, K., Kaleem, B., Jamal, S., 2022. Chemotherapy induced histopathological changes in retinoblastoma, assessment of high risk predictive factors & its correlation with comorbid conditions. *Pak. J. Med. Sci.* 38, 362–368. <https://doi.org/10.12669/pjms.38.ICON-2022.5786>

# LAMPIRAN 1

## REKOMENDASI PERSETUJUAN ETIK



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI  
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN  
 KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN  
 RSPN UNIVERSITAS HASANUDDIN  
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR  
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu



JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.  
 Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

### REKOMENDASI PERSETUJUAN ETIK

Nomor : 417/UN4.6.4.5.31/ PP36/ 2024

Tanggal: 10 Juni 2024

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH24050289	No Sponsor	
Peneliti Utama	<b>dr. Nurul Qalbi Ramadhani</b>	Sponsor	
Judul Peneliti	Karakteristik Pasien Retinoblastoma Berdasarkan Amplifikasi Gen MYCN		
No Versi Protokol	1	Tanggal Versi	29 April 2024
No Versi PSP	1	Tanggal Versi	29 April 2024
Tempat Penelitian	RSUP. Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku	Frekuensi review lanjutan
		10 Juni 2024 sampai 10 Juni 2025	
Ketua KEP Universitas Hasanuddin	<b>Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)</b>	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	<b>dr. Firdaus Hamid, PhD, SpMK(K)</b>	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

## LAMPIRAN 2 DATA INDUK

No.	RM	Nama	Tanggal lahir (usia)	Lateralitas	Gejala awal	Usia sadar gejala	dalam bulan	Usia terdiagnosa	dalam bulan	IO / EO	PA	Ekspresi MYCN gene	Enukleasi	Terapi	Visus
1	926700	Wa Sutri	24-4-2013 (11 thn)	uni	proptosis	6 tahun 9 bulan	81	7 tahun 9 bulan	93	EO	fibrotik luas	0,07140	sec	secondary enuk (sebelumnya terapi kemo methotrexate + ARA-C/ intratekal) (dengan doxorubicin /iv) (cytarabine iv)	OD: NLP OS: FFO (+)
2	924453	Izzat Ikra	21-5-2016 (8 thn)	uni	leukokoria	2 tahun	24	4 tahun 6 bulan	54	IO	differentiated rb	0,00552	sec	secondary enuk (sebelumnya terapi kemo VEC)	OD: NLP OS: 6/6
3	929290	M. Januar Rizkullah	30-1-2019 (5 thn)	uni	Leukokoria	1 tahun 9 bulan	21	2 tahun 1 bulan	25	IO	nekrotik, fibrosis, kalsifikasi	no	sec	secondary enuk (sebelumnya terapi kemo VEC)	sulit dievaluasi
4	925421	Najwa Salsabilah	28-1-2020 (4 thn)	uni	leukokoria	6 bulan	6	1 tahun	12	IO	undifferentiated	no	sec	secondary enuk (sebelumnya terapi kemo VEC)	OD: FFO (+) OS: BTL (-)
5	948591	Cintya Bella Kaluti	4-7-2016 (8 thn)	uni	leukokoria	5 tahun 1 bulan	61	5 tahun 3 bulan	63	IO	differentiated rb	0,15501	prim	primary	OD: NLP OS: 20/20
6	948169	Hanif Hidayatullah	10-2-2019 (5 thn)	uni	leukokoria	3 bulan	3	2 tahun 8 bulan	32	IO	differentiated rb	0,81751	prim	Primary	OD: FFO (+) OS: FFL (+)
7	951958	Zainul Muttaqin	14-5-2021 (3 thn)	uni	leukokoria	2 bulan	2	4 bulan	4	IO	differentiated rb	0,13005	prim	primary	OD: BTL (-) OS: BTL (+)
8	963335	Andi Akeel Alfarezel	17-2-2021 (3 thn)	uni	leukokoria	10 bulan	10	1 tahun	12	IO	differentiated rb	2,68759	prim	primary	OD: BTL (-) OS: FFO (+)
9	979352	Nur Arhaisyah Putri	14-1-2020	bilateral	proptosis	2 tahun 1 bulan	25	2 tahun 4 bulan	28	EO	rb	13,95959	sec	secondary enuk (sebelumnya terapi kemo VEC)	Od ffo, os nlp
10	979238	Fariq Atallah Yusuf	19-12-2019 (5 thn)	uni	Leukokoria	2 tahun 7 bulan	31	2 tahun 8 bulan	32	IO	differentiated rb	no	prim	primary	OD: FFL (+) OS: FFO (+)
11	951792	Muh Al Hafiz	30-5-2019	uni	Proptosis	2 tahun 2 bulan	26	2 tahun 5 bulan	29	EO	Fibrosis, kalsifikasi	0,06168	sec	secondary enuk (sebelumnya terapi kemo VEC)	Od ffo, os sdn
12	990647	Micayla Az Zahra M. Lutfi	23-6-2019	Bilateral	Leukokoria	1 tahun 7 bulan	19	2 tahun 2 bulan	26	EO	rb	0,79884	prim	primary	Ods nlp
13	990362	Muhammad Rasyidan	25-7-2020 (4 thn)	bilateral	Leukokoria + proptosis	1 bulan	1	2 tahun 1 bulan	25	IO	differentiated rb	no	sec	secondary	OD: BTL (-) OS: BTL (+)
14	947985	Patricia Carlisa Vantura	29-3-2020 (4 thn)	bilateral	leukokoria	7 bulan	7	1 tahun 7 bulan	19	IO	nekrotik, fibrosis, kalsifikasi	no	sec	secondary enuk (sebelumnya terapi kemo VEC)	OD: FFO (+) OS: BTL (+)
15	952578	Aidah Najwa Rachim	13-6-2021 (3 thn)	Bilateral	Leukokoria	1	1	5 bulan	5	IO	undifferentiated	0,31178	sec	ods secondary	
16	993566	Aqinara Qaila Irawan	22-3-2018 (6 thn)	Uni	leukokoria	3 tahun 11 bulan	47	4 tahun 7 bulan	55	IO	differentiated rb	no	prim	primary	OD: 20/20 OS: NLP

No.	RM	Nama	Tanggal lahir (usia)	Lateralitas	Gejala awal	Usia sadar gejala	dalam bulan	Usia terdiagnosa	dalam bulan	IO / EO	PA	Ekspresi MYCN gene	Enukleasi	Terapi	Visus
17	742766	Muh. Daffa Azka Azfar	15-5-2015 (9 thn)	uni	Proptosis	6 tahun 6 bulan	78	7 tahun 1 bulan	85	EO	undifferentiated	no	sec	secondary enuk (sebelumnya terapi kemo VEC)	Od 20/30, os sdn
18	971458	Nur Khodija	19-2-2017 (7 thn)	uni	leukokoria	4 tahun 1 bulan	49	5 tahun	60	EO	Rb	no	sec	secondary enuk (sebelumnya terapi kemo VEC)	OD: LP OS: 20/20
19	986999	Uwais Idris Abdul Rahman	4-5-2019 (5 thn)	bilateral	os proptosis	1 tahun 6 bulan	18	2 tahun 2 bulan	26	EO	nekrotik, fibrosis, kalsifikasi	2.09149	sec	secondary enuk (sebelumnya terapi kemo VEC)	sulit dievaluasi
20	967357	Aisya Ailani	12-7-2018 (6 thn)	uni	mata merah	2 tahun 10 bulan	34	3 tahun 7 bulan	43	EO	nekrotik	no	sec	secondary enuk (sebelumnya terapi kemo VEC)	OD: sulit dievaluasi OS: FFO (+)
21	842606	Muhammad Izqian Khalil	9-5-2018	Uni	leukokoria	3 tahun 10 bulan	46	4 tahun 1 bulan	49	IO	nekrotik fibrosis	no	sec	secondary enuk (sebelumnya terapi kemo VEC)	Od lp, os 20/30
22	969952	Abil Shidiq Arsalaan S	12-11-2018 (5thn)	Uni	leukokoria, tidak melihat	3 tahun	36	3 tahun 11 bulan	47	IO	nekrotik, kalsifikasi	7.86373	sec	secondary enuk (sebelumnya terapi kemo VEC)	
23	960940	Al hafidz Al Qadri	2-6-2018 (6 thn)	Uni	leukokoria	2 tahun	24	3 tahun 6 bulan	42	IO	undifferentiated	2.54397	sec	secondary enuk (sebelumnya terapi kemo VEC)	OD: NLP OS: 20/20
24	1019844	Atita Nur Aufa Amal	28-1-2023 (1 thn )	Uni	leukokoria, tidak melihat	2 bulan	2	3 bulan	3	IO	differentiated rb	22.30963	prim	primary	OD: BTL (+) OS: BTL (-)
25	975394	Achmad Haidir Rusmin	2-10-2019 (5 thn)	Uni	leukokoria, semakin membesar	2 tahun 6 bulan	30	3 tahun 2 bulan	38	EO	fibrosis, kalsifikasi	no	sec	secondary enuk (sebelumnya terapi kemo VEC)	OD: sdn OS: FFO (+)
26	1020090	Nabil Helmi Alam	2-3-2015	Uni	Proptosis	7 tahun 6 bulan	90	8 tahun 3 bulan	99	EO	differentiated rb	0.08659	sec	Secondary	
27	961827	Afhan Ramadan	23-5-2018 (6 thn)	uni	Leukokoria	1 tahun	12	5 tahun	60	EO	nekrotik, fibrosis, kalsifikasi	0.52584	sec	secondary	OD: 20/20 OS: NLP
28	1021880	Amsal Salomo	18-10-2020 (4 thn)	Bilateral	Lekokoria	3 bulan	3	2tahun 10 bulan	34	EO	nekrosis kalsifikasi	0.30994	sec	secondary enuk (sebelumnya terapi kemo VEC)	Od nlp, os sdn
29	1033462	Freya Arabell Tandil Datu	25-9-2021 (3 thn)	Uni	leukokoria, strabismus	1 tahun 6 bulan	18	1 tahun 10 bulan	22	IO	differentiated rb	11.67269	prim	primary	OD: FFO (+) OS: BTL (-)
30	1042283	Dinara Larissa Helmi	17-4-2019 (5 tahun)	Uni	leukokoria, strabismus	4 tahun 4 bulan	48	4 tahun	52	IO	differentiated rb	0.38525	prim	primary	OD: 20/20 OS: NLP
31	1053303	Muh. Al Ghazali Budiman	9-2-2021 (3 thn)	Uni	leukokoria	2 tahun 4 bulan	28	2 tahun 8 bulan	32	EO	undifferentiated	no	prim	primary	OD: NLP OS: FFO (+)

**LAMPIRAN 3**  
**HASIL EKSPRESI mRNA GEN MYCN**

Target	Nomor sampel	Biological Group Sample	Control	Expression	Expression SEM	Corrected Expression SEM	Mean Cq	Cq SEM	P-Value
MYCN	1	EO_1		0,07140	0,00000	0,00000	36,49	0,00000	
MYCN	2	IO_2		0,00552	0,00000	0,00000	42,33	0,00000	
MYCN	5	IO_5		0,15501	0,00000	0,00000	32,99	0,00000	
MYCN	6	IO_6		0,81751	0,00000	0,00000	36,17	0,00000	
MYCN	7	IO_7		0,13005	0,00000	0,00000	36,07	0,00000	
MYCN	8	IO_8		2,68759	0,00000	0,00000	34,36	0,00000	
MYCN	9	EO_9		13,95959	0,00000	0,00000	31,21	0,00000	
MYCN	11	EO_11		0,06168	0,00000	0,00000	36,55	0,00000	
MYCN	12	EO_12		0,79884	0,00000	0,00000	35,37	0,00000	
MYCN	15	IO_15		0,31178	0,00000	0,00000	38,29	0,00000	
MYCN	19	EO_19		2,09149	0,00000	0,00000	35,09	0,00000	
MYCN	22	IO_22		7,86373	0,00000	0,00000	32,16	0,00000	
MYCN	23	IO_23		2,54397	0,00000	0,00000	33,50	0,00000	
MYCN	24	IO_24		22,30963	0,00000	0,00000	28,46	0,00000	
MYCN	26	EO_26		0,08659	0,00000	0,00000	37,00	0,00000	
MYCN	27	EO_27		0,52584	0,00000	0,00000	36,21	0,00000	
MYCN	28	EO_28		0,30994	0,00000	0,00000	34,97	0,00000	
MYCN	29	IO_29		11,67269	0,00000	0,00000	26,99	0,00000	
MYCN	30	IO_30		0,38525	0,00000	0,00000	36,26	0,00000	
MYCN	32	IO_32		1,68904	0,00000	0,00000	31,96	0,00000	

upregulated

downregulated

no expression = 12 sampel

**LAMPIRAN 4**  
**STATISTIK**  
**HASIL DATA SPSS**

Descriptive Statistics					
	N	Minimum	Maximum	Mean	Std. Deviation
Usia sadar gejala	18	2.00	90.00	28.1111	26.44615
Usia diagnosis	20	3.00	99.00	36.7000	27.40169
Valid N (listwise)	18				

Chi-Square Tests					
	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.586 <sup>a</sup>	1	.444		
Continuity Correction <sup>a</sup>	.082	1	.774		
Likelihood Ratio	.600	1	.439		
Fisher's Exact Test				.642	.392
Linear-by-Linear Association	.557	1	.456		
N of Valid Cases	20				
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 2.80.					
b. Computed only for a 2x2 table					

Chi-Square Tests					
	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.849 <sup>a</sup>	1	.174		
Continuity Correction <sup>b</sup>	.970	1	.325		
Likelihood Ratio	1.905	1	.168		
Fisher's Exact Test				.266	.163
Linear-by-Linear Association	1.791	1	.181		
N of Valid Cases	32				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 4.81.

b. Computed only for a 2x2 table

Test Statistics <sup>a,b</sup>					
	Jenis kelamin	Lateralitas	Usia sadar gejala	Usia sadar gejala	Usia sadar gejala
Chi-Square	.128	.339	.595	.438	.557
df	1	1	1	1	1
Asymp. Sig.	.721	.560	.440	.508	.456

Test Statistics <sup>a,b</sup>					
	Usia diagnosis	Usia diagnosis	Usia diagnosis	Grading	Histopatologi
Chi-Square	3.729	2.085	2.413	.557	.028
df	1	1	1	1	1
Asymp. Sig.	.053	.149	.120	.456	.866

Test Statistics <sup>a,b</sup>			
	Terapi Enukleasi	Invasi Nervus Optik	Histopatologi
Chi-Square	.033	.572	2.181
df	1	1	1
Asymp. Sig.	.856	.449	.140

a. Kruskal Wallis Test

b. Grouping Variable: Gen MYCN

Means and Medians for Survival Time						
Mean <sup>a</sup>				Median		
Estimate	Std. Error	95% Confidence Interval		Estimate	Std. Error	95% Confidence Interval
		Lower Bound	Upper Bound			Lower Bound
2.140	.879	.416	3.863	.087	.066	.000

### Means and Medians for Survival Time

Median<sup>a</sup>


95% Confidence Interval

Upper Bound

.216

a. Estimation is limited to the largest survival time if it is censored.

**Survival Function**



**Hazard Function**

